Report on a biopharma's midyear financial and commercial update highlighting global sales momentum and pipeline progress in oncology.
Key Takeaways
- 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year
- Key financial and operational metrics maintained a steady upward trajectory
- Benefits of this dual-engine growth model are increasingly taking shape